Cost-effectiveness of endovascular treatment for acute ischemic stroke in China: evidence from Shandong Peninsula

Lu Han,Kuixu Lan,Dejian Kou,Zehua Meng,Jin Feng,Elizabeth Maitland,Stephen Nicholas and Jian Wang
DOI: https://doi.org/10.1186/s13561-024-00513-7
2024-06-06
Health Economics Review
Abstract:Recently, the endovascular treatment (EVT) of acute ischemic stroke has made significant progress in many aspects. Intravenous thrombolysis (IVT) is usually recommended before endovascular treatment in clinical practice, but the value of the practice is controversial. The latest meta-analysis evaluation was that the effect of EVT versus EVT plus IVT did not differ significantly. The cost-effectiveness analysis of EVT plus IVT needs further analysis. This study assesses the health benefits and economic impact of EVT plus IVT in Shandong Peninsula of China.
economics,health policy & services
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to evaluate the health benefits and economic impact of using endovascular treatment (EVT) alone versus combined intravenous thrombolysis (IVT) and endovascular treatment (EVT + IVT) in patients with acute ischemic stroke (AIS) in Shandong Province, China. Specifically, the research objectives are: 1. **Compare the cost-effectiveness of the two treatment methods**: Assess the cost-effectiveness of using EVT alone and EVT + IVT over different time frames through the incremental cost-effectiveness ratio (ICER). 2. **Analyze actual medical costs and health outcomes**: Utilize real-world data from the public hospital database in Shandong Province to collect and analyze the direct treatment costs, indirect costs, and health outcomes of EVT and EVT + IVT. 3. **Conduct sensitivity analysis**: Validate the robustness of the economic evaluation model through one-way sensitivity analysis and Monte Carlo probabilistic sensitivity analysis. ### Background - **Epidemiology of Stroke**: Stroke is the second leading cause of death globally and the leading cause of disability in China. Ischemic stroke accounted for 83% of hospitalized cerebrovascular disease patients in China in 2019, with an annual recurrence rate between 9.6% and 17.7%. - **Current Treatment Status**: The treatment window for acute ischemic stroke is 8 hours, with common treatments including endovascular thrombolysis (EVT) and intravenous thrombolysis (IVT). Recent clinical evidence suggests that EVT is more effective than IVT, but EVT may cause reperfusion injury, prolonging prognosis. - **Economic Factors**: In developing countries like China, economic factors are crucial considerations for patients and their families when choosing treatment options. Therefore, evaluating the cost-effectiveness of EVT and EVT + IVT is significant for optimizing healthcare resource allocation. ### Methods - **Model Structure**: The study designed a health economics decision model, including two branches: EVT alone and EVT + IVT. The model consists of a decision tree and a Markov state transition model, with a time frame from 3 months to 99% patient mortality. - **Data Sources**: Data were sourced from the hospital information systems (HIS) of three major public hospitals in Shandong Province, including ischemic stroke patients from 2013 to 2023. Direct treatment costs, indirect costs, and health utility values were extracted from HIS and published literature. - **Statistical Analysis**: The cost-effectiveness of the two treatment methods was assessed by calculating the incremental cost-effectiveness ratio (ICER), and the robustness of the model was validated using one-way sensitivity analysis and Monte Carlo probabilistic sensitivity analysis. ### Results - **Cost-Effectiveness Analysis**: EVT alone was more cost-effective than EVT + IVT in both the short term and long term. At 99% AIS patient mortality, the ICER for each additional quality-adjusted life year (QALY) was 696,399.30 RMB, exceeding the willingness-to-pay threshold in Shandong (3 times the per capita GDP). - **Sensitivity Analysis**: The direct treatment costs of EVT and EVT + IVT had the most significant impact on ICER. Even within the range of other parameter changes, EVT remained more cost-effective than EVT + IVT. ### Conclusion - **Main Conclusion**: Based on real-world evidence from Shandong Province and a meta-analysis of six randomized controlled trials, EVT alone is more cost-effective than EVT + IVT. Although this conclusion aligns with most existing research recommendations, its applicability in other regions needs to be reassessed. - **Policy Recommendations**: The study results can provide a reference for other regions in China, but their applicability in other areas should be carefully considered. ### Significance This study provides important economic evaluation evidence for treatment choices in patients with acute ischemic stroke, helping to optimize healthcare resource allocation, reduce medical cost burdens, and improve patient health benefits.